Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD asserts safety of Leptospira vaccine
Vets are reminded to tailor vaccination programmes for specific animals.
Statement follows reports of adverse events from vaccinated dogs.

The Veterinary Medicines Directorate (VMD) has reaffirmed the safety of the Leptospira vaccine, after adverse events were reported for L2 and L4 vaccines.

The statement comes amidst media reports and social media post which raised concerns amidst adverse events in vaccinated dogs.

There are several Leptospira vaccines authorised for use in the UK that either contain two strains (L2) or four strains (L4) of Leptospira bacteria. The VMD says that the overall incidence of adverse events remains rare, and therefore its benefits outweigh its risks.

In its latest analysis of adverse events in L2 vaccine products, the VMD says that incidence of adverse events combined was 0.016 per cent. Meanwhile, for L4 vaccine products, this figure was 0.040 per cent.

This means that, for every 10,000 estimated animals treated, the VMD has received fewer than two adverse events for L2 and fewer than four adverse events for L4.

The VMD’s data for adverse events involving death, including euthanasia, was similarly low. For all L2 vaccine products the percentage was at 0.0017 per cent, while for L4 vaccine products it was 0.0033 per cent.

The VMD says that, therefore, incidence of adverse effects was rare and those involving death was very rare.

There has also been concern from the veterinary industry and members of the public that some Leptospira vaccines are being withdrawn from the market. While the VMD says it cannot prevent such occurrences, it is reassuring pet owners that both L2 and L4 Leptospira vaccines remain available.

Veterinary surgeons are being reminded to tailor vaccination programmes for each individual animal. These programmes should be informed by the local disease risk, as well as other potential risks that will be listed in the Summary of Product Characteristics and product information.

Image © Maria Sbytova/Shutterstock.com

Become a member or log in to add this story to your CPD history

Voting opens for BEVA Council

News Story 1
 Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.

There are five candidates standing for four available places on Council. They are:

  • Alexandre Triguino
  • Angela Jones
  • Beth Bryant
  • Holly Rees
  • Hugh Somerville
Full profiles for each candidate can be found on the BEVA website

Click here for more...
News Shorts
Government releases latest bluetongue statistics

APHA has confirmed the number of bluetongue cases that have been logged in the UK since 1 July 2026.

The total number of BTV-3 cases, as of 6 August, is 187. This includes 183 cases in England and four cases in Wales.

There have been no recorded cases in Scotland and Northern Ireland.

The location of premises in Great Britain where at least one animal has tested positive by PCR for BTV-3, BTV-8 or BTV-12 is available on the bluetongue case map. All livestock keepers in Great Britain are urged to familiarise themselves with nation-specific bluetongue control policies.

Bluetongue virus is a notifiable disease. It is a legal requirement that any suspicions, even if livestock has been vaccinated, are reported immediately.